AR077316A2 - Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 - Google Patents
Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6Info
- Publication number
- AR077316A2 AR077316A2 ARP100102573A ARP100102573A AR077316A2 AR 077316 A2 AR077316 A2 AR 077316A2 AR P100102573 A ARP100102573 A AR P100102573A AR P100102573 A ARP100102573 A AR P100102573A AR 077316 A2 AR077316 A2 AR 077316A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- fluorinated
- alkoxy
- halogen
- radical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
- C07D211/28—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Métodos de preparacion, composiciones farmacéuticas y uso de los mismos. Reivindicacion 1: Un compuesto de la formula 1 caracterizado porque n es 0,1 o 2; G es CH2 o CHR3; R1 es H, alquilo C1-6, alquilo C1-6 sustituido por cicloalquilo C3-6, hidroxialquilo C1-6, alquilo fluorado C1-6, cicloalquilo C3-6, cicloalquilo fluorado C3-6, alquenilo C3-6, alquenilo fluorado C3-6, formilo, acetilo, propionilo o bencilo; R2, R3 y R4 son, en forma independiente entre sí, H, metilo, fluorometilo, difluorometilo, o trifluorometilo; A es 1,4-fenileno o 1,3-fenileno, que es opcionalmente sustituido por uno, dos, tres o cuatro sustituyentes seleccionados entre halogeno, alquilo C1-4, alcoxi C1-4, alquilo fluorado C1-4 y alcoxi fluorado C1-4; E es NR5 o CH2, en donde R5 es H o alquilo C1-3; Ar es un radical de la formula A, B, C, D, E, F o G en donde Ra es halogeno, hidroxilo, alquilo C1-6, alquilo fluorado C1-6, hidroxialquilo C1-6, alcoxi C1-6-alquilo C1-6, alquenilo C2-6, alquenilo fluorado C2-6, cicloalquilo C3-6, cicloalquilo fluorado C3-6, alcoxi C1-6, hidroxialcoxi C1-6, alcoxi C1-6-alcoxi C1-6, alcoxi C1-6 fluorado, alquiltio C1-6, alquiltio fluorado C1-6, alquilsulfinilo C1-6, alquilsulfinilo fluorado C1-6, alquilsulfonilo C1-6, alquilsulfonilo fluorado C1-6, fenilsulfonilo, piridilsulfonilo, benciloxi, fenoxi, fenilo, donde el fenilo y el radical piridilo en los ultimos 5 radicales pueden no estar sustituidos o pueden tener entre 1 y 3 sustituyentes seleccionados entre alquilo C1-4, alquilo fluorado C1-4 y halogeno, CN, nitro, alquilcarbonilo C1-6, alquilcarbonilo fluorado C1-6, alquilcarbonilamino C1-6, alquilcarbonilamino fluorado C1-6, carboxi, NH-C(O)-NR6R7, NR6R7, NR6R7-C1-6-alquileno, O-NR6R7, donde R6 y R7 son, en forma independiente entre sí, H, alquilo C1-4, alquilo fluorado C1-4 o alcoxi C1-4 o pueden formar, junto con N, un anillo saturado o insaturado de 4, 5, o 6 miembros, R9-CO-NR6-C1-6-alquileno, donde R6 tiene los valores que se han definido y R9 es alquilo C1-4 o fenilo, donde el radical fenilo puede no estar sustituido o puede tener entre 1 y 3 sustituyentes seleccionados entre alquilo C1-4, alquilo fluorado C1-4 y halogeno, CH2-piridilo, donde el radical piridilo puede no estar sustituido o puede tener entre 1 y 3 sustituyentes seleccionados entre alquilo C1-4, alquilo fluorado C1-4 y halogeno, o es un anillo heterocíclico saturado o insaturado, aromático o no aromático de 3 a 7 miembros que comprende como miembros del anillo 1, 2, 3 o 4 heteroátomos seleccionados entre N, O y S y/o 1, 2 o 3 grupos que contienen heteroátomos seleccionados entre NR8, donde R8 es H, alquilo C1-4, alquilo fluorado C1-4, alquilcarbonilo C1-4 o alquilcarbonilo fluorado C1-4, SO, SO2 y CO, y donde el heterociclo puede tener 1, 2 o 3 sustituyentes seleccionados entre hidroxi, halogeno, alquilo C1-6, alquilo fluorado C1-6, alcoxi C1-6, alcoxi fluorado C1-6, alquiltio C1-6, alquiltio fluorado C1-6, NR6R7-C1-6-alquileno, donde R6 y R7 tienen los valores que se han definido, carboxilo y alquiloxicarbonilo C1-4; Rb y Rc, en forma independiente entre sí, son H, halogeno, CH3, OCH3, CH2F, OCH2F, CHF2, OCHF2, CF3, OCF3, CH2CH2F, OCH2CH2F, CH2CHF2, OCH2CHF2, CH2CF3 o OCH2CF3; Rd se define como Ra; Re es H o se define como Ra; Rf se define como Ra; k es 0, 1, 2 o 3; y j es 0, 1, 2, 3 o 4; con la salvedad de que Ra no es F, CH2F, CHF2, CF3 o OCF3 si A es 1,4-fenileno, Ar es un radical de la formula (A) y Rb y Rc son H o halogeno; excepto los compuestos, donde R1 es propilo, G es CH2, n es 1, A es 1,4-fenileno, E es NH, Ar es un radical de formula (F) y Rd es halogeno, alquilo C1-6, alquenilo C2-6 o un atillo heteroaromático de 5 miembros; y sales de adicion ácida de los mismos toleradas fisiologicamente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US79313906P | 2006-04-19 | 2006-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR077316A2 true AR077316A2 (es) | 2011-08-17 |
Family
ID=38231700
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101658A AR060526A1 (es) | 2006-04-19 | 2007-04-18 | Compuestos heterociclicos para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 |
ARP100102573A AR077316A2 (es) | 2006-04-19 | 2010-07-15 | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070101658A AR060526A1 (es) | 2006-04-19 | 2007-04-18 | Compuestos heterociclicos para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 |
Country Status (19)
Country | Link |
---|---|
US (1) | US8642642B2 (es) |
EP (1) | EP2029528A1 (es) |
JP (1) | JP2009534354A (es) |
KR (1) | KR20080112394A (es) |
CN (1) | CN101421234A (es) |
AR (2) | AR060526A1 (es) |
AU (1) | AU2007239494A1 (es) |
BR (1) | BRPI0710177A2 (es) |
CA (1) | CA2648891A1 (es) |
CR (1) | CR10371A (es) |
DO (1) | DOP2007000077A (es) |
EC (1) | ECSP088826A (es) |
MX (1) | MX2008013434A (es) |
NZ (1) | NZ572761A (es) |
PE (1) | PE20080191A1 (es) |
RU (1) | RU2451012C2 (es) |
TW (1) | TW200812961A (es) |
UY (1) | UY30295A1 (es) |
WO (1) | WO2007118899A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2583983C (en) * | 2004-10-14 | 2013-07-16 | Abbott Gmbh & Co. Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
ES2358549T3 (es) * | 2006-11-09 | 2011-05-11 | F. Hoffmann-La Roche Ag | Arilsulfonil, pirrolidinas como inhibidores de 5-ht6. |
CA2718399A1 (en) * | 2008-03-06 | 2009-09-11 | Roger P. Horbay | A system, method and computer program for retention and optimization of gaming revenue and amelioration of negative gaming behaviour |
WO2010125134A1 (en) * | 2009-04-30 | 2010-11-04 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
WO2012059432A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
PL395470A1 (pl) * | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Sulfonamidowe pochodne amin alicyklicznych do leczenia chorób osrodkowego ukladu nerwowego |
CN106902112B (zh) * | 2017-03-07 | 2019-06-04 | 中国医学科学院医药生物技术研究所 | Imb-a6作为雄激素受体拮抗剂的应用 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2139750T3 (es) | 1993-08-06 | 2000-02-16 | Upjohn Co | 2-aminoindanos como ligandos selectivos d3 de la dopamina. |
WO1996023760A1 (en) | 1995-02-01 | 1996-08-08 | Pharmacia & Upjohn Company | 2-aminoindans as selective dopamine d3 ligands |
US5646180A (en) * | 1995-12-05 | 1997-07-08 | Vertex Pharmaceuticals Incorporated | Treatment of the CNS effects of HIV |
ES2192677T3 (es) | 1996-05-30 | 2003-10-16 | Baker Hughes Inc | Control de la corrosion por el acido naptenico con compuestos de tiofosforo. |
DZ2376A1 (fr) | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
TW450954B (en) | 1998-05-14 | 2001-08-21 | Pharmacia & Amp Upjohn Company | Phenylsulfonamide-phenylethylamines useful as dopamine receptors |
HUP0102622A3 (en) * | 1998-07-20 | 2002-12-28 | Merck Patent Gmbh | Biphenyl derivatives, process for producing them and pharmaceutical compositions containing them |
US20040127502A1 (en) * | 2001-01-31 | 2004-07-01 | Synaptic Pharmaceutical Corporation | Use of GAL3 antagonist for treatment of depression |
WO2002083863A2 (en) | 2001-04-17 | 2002-10-24 | Sepracor, Inc. | Thiazole and other heterocyclic ligands and use thereof |
NZ528450A (en) * | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
GB0321473D0 (en) | 2003-09-12 | 2003-10-15 | Glaxo Group Ltd | Novel compounds |
WO2005037830A1 (en) | 2003-10-10 | 2005-04-28 | Wyeth | Piperidinylchromen-6-ylsulfonamide compounds as 5-hydroxytryptamine-6 ligands |
GB0411421D0 (en) | 2004-05-21 | 2004-06-23 | Glaxo Group Ltd | Novel compounds |
CA2583983C (en) | 2004-10-14 | 2013-07-16 | Abbott Gmbh & Co. Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor |
AU2005315923A1 (en) | 2004-12-16 | 2006-06-22 | F. Hoffmann-La Roche Ag | Piperazinyl pyridine derivatives as anti-obesity agents |
AU2006216652A1 (en) * | 2005-02-23 | 2006-08-31 | Prexa Pharmaceuticals, Inc. | Multimediator 5-HT6 receptor antagonists, and uses related thereto |
WO2006096439A2 (en) | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
CA2648892A1 (en) * | 2006-04-19 | 2007-10-25 | Abbott Gmbh & Co. Kg | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor |
-
2007
- 2007-04-18 BR BRPI0710177-5A patent/BRPI0710177A2/pt not_active IP Right Cessation
- 2007-04-18 EP EP07728269A patent/EP2029528A1/en not_active Withdrawn
- 2007-04-18 AU AU2007239494A patent/AU2007239494A1/en not_active Abandoned
- 2007-04-18 NZ NZ572761A patent/NZ572761A/en not_active IP Right Cessation
- 2007-04-18 CA CA002648891A patent/CA2648891A1/en not_active Abandoned
- 2007-04-18 RU RU2008145597/04A patent/RU2451012C2/ru not_active IP Right Cessation
- 2007-04-18 WO PCT/EP2007/053807 patent/WO2007118899A1/en active Application Filing
- 2007-04-18 US US12/297,350 patent/US8642642B2/en active Active
- 2007-04-18 PE PE2007000479A patent/PE20080191A1/es not_active Application Discontinuation
- 2007-04-18 UY UY30295A patent/UY30295A1/es not_active Application Discontinuation
- 2007-04-18 KR KR1020087028322A patent/KR20080112394A/ko not_active Application Discontinuation
- 2007-04-18 JP JP2009505887A patent/JP2009534354A/ja active Pending
- 2007-04-18 CN CNA2007800135172A patent/CN101421234A/zh active Pending
- 2007-04-18 TW TW096113699A patent/TW200812961A/zh unknown
- 2007-04-18 DO DO2007000077A patent/DOP2007000077A/es unknown
- 2007-04-18 AR ARP070101658A patent/AR060526A1/es not_active Application Discontinuation
- 2007-04-18 MX MX2008013434A patent/MX2008013434A/es not_active Application Discontinuation
-
2008
- 2008-10-16 EC EC2008008826A patent/ECSP088826A/es unknown
- 2008-10-16 CR CR10371A patent/CR10371A/es not_active Application Discontinuation
-
2010
- 2010-07-15 AR ARP100102573A patent/AR077316A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
TW200812961A (en) | 2008-03-16 |
RU2451012C2 (ru) | 2012-05-20 |
AR060526A1 (es) | 2008-06-25 |
JP2009534354A (ja) | 2009-09-24 |
US8642642B2 (en) | 2014-02-04 |
BRPI0710177A2 (pt) | 2012-05-29 |
CA2648891A1 (en) | 2007-10-25 |
US20090306175A1 (en) | 2009-12-10 |
RU2008145597A (ru) | 2010-05-27 |
KR20080112394A (ko) | 2008-12-24 |
PE20080191A1 (es) | 2008-03-10 |
ECSP088826A (es) | 2008-11-27 |
CR10371A (es) | 2008-12-11 |
MX2008013434A (es) | 2009-01-26 |
CN101421234A (zh) | 2009-04-29 |
WO2007118899A1 (en) | 2007-10-25 |
DOP2007000077A (es) | 2008-01-15 |
AU2007239494A1 (en) | 2007-10-25 |
UY30295A1 (es) | 2007-11-30 |
NZ572761A (en) | 2011-09-30 |
EP2029528A1 (en) | 2009-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR077316A2 (es) | Compuestos heterociclicos apropiados para tratar trastornos que responden a la modulacion del receptor de serotonina 5ht6 | |
AR111425A2 (es) | MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN | |
NI201200184A (es) | Morfolinopirimidinas y su uso en terapia | |
PE20080970A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos | |
AR072791A1 (es) | DERIVADOS DE TIAZOLIDIN-2, 4-DIONA, MÉTODOS PARA SU PREPARACIoN, COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE Y SU USO EN LA ELABORACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DEL CÁNCER. | |
CR11857A (es) | Compuestos pirazolicos 436 | |
AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
CU20120084A7 (es) | Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación | |
BR112014032809A8 (pt) | urolitinas, usos de uma quantidade eficaz de uma urolitina ou um sal farmaceuticamente aceitável da mesma e composição compreendendo as mesmas | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR055916A1 (es) | Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica | |
GT200900280A (es) | Derivados de 2 piridin carboxamida como moduladores de los canales de sodio | |
AR058703A1 (es) | Triazolopiridazinas inhibidoras de tirosinquinasas, metodo de preparacion, composiciones farmaceuticas que las contienen y usos terapeuticos en el tratamiento del cancer | |
ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
AR082826A2 (es) | Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos | |
AR078045A1 (es) | Derivados de pirimidina, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer | |
AR054320A1 (es) | Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas | |
AR051735A1 (es) | Inhibidores pirrolicos de la proteina quinasa erk, sintesis e intermediarios de los mismos. | |
AR078786A1 (es) | Derivados de la cromenona | |
AR072578A1 (es) | Compuestos de piperidina puenteada tipo quinoxalina sustituida y los usos de los mismos | |
AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
ECSP12012338A (es) | Triazolopiridinas sustituidas | |
UY27852A1 (es) | Difenilazatidinonas cationicamente sustituidas, procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso. | |
AR058319A1 (es) | N-(fluoropirazinil)fenilsulfonamidas como moduladores del receptor ccr4 de quimioquinas | |
PE20141527A1 (es) | Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, preparacion de los mismos y su uso terapeutico de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |